Transaction · 0001918845-26-000031

Doyle Mittie

Doyle Mittie, CMO, reported an open-market or private sale at Avalo Therapeutics, Inc. involving 679.000000 shares for an estimated $13580.00. Reported holdings after the transaction were 51776.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCMO
AVTXAvalo Therapeutics, Inc.
Filing timeSep 01
Trade dateAug 28, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$19.34
Pre-filing
1mo ago -1.7%1w ago +2.5%1d ago +3.7%
Returns since
7d +0.0%30d +0.0%90d +0.0%180d +0.0%1y +0.0%

AVTX price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
AVTX since 2026-09-01Filed 3 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001918845-26-000031
Common Stock
Transaction date
Aug 28, 2026
Filed Sep 01, 2026, 08:38 PM · 4d delay
Shares
679 sh
$2.00k per share
Estimated value
-$1.35M
Computed from shares × price
Holdings after
51.7k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Cluster Selling Direct Ownership 10b5-1 Detected
-4score
Filing-only score

-4

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Medical Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

  2. F2

    The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's con…

Original filing · 0001918845-26-000031
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

AVTX